Sunday, September 7, 2025
  • Login
Forbes 40under40
  • Home
  • Technology
  • Innovation
  • Real Estate
  • Leadership
  • Money
  • Lifestyle
No Result
View All Result
  • Home
  • Technology
  • Innovation
  • Real Estate
  • Leadership
  • Money
  • Lifestyle
No Result
View All Result
Forbes 40under40
No Result
View All Result
Home Leadership

Roche to acquire cell therapy maker Poseida Therapeutics in US$1.5 billion deal

by Yurie Miyazawa
in Leadership
Roche to acquire cell therapy maker Poseida Therapeutics in US.5 billion deal
Share on FacebookShare on Twitter


SWITZERLAND’S Roche will acquire its US collaboration partner Poseida Therapeutics in a cash deal worth up to US$1.5 billion, banking on complex immune cell therapies against several types of blood cancer.

Roche will pay US$9 per share in cash and stockholders will also receive a non-tradeable contingent value right for up to US$4 per share based on achievements, the companies said in a statement on Tuesday (Nov 26), taking the deal value to up to around US$1.5 billion.

It is expected to close in the first quarter of 2025.

“We have worked closely with Roche through our collaboration focused on hematologic malignancies, and we are excited to join Roche to work as colleagues together across our pipeline and future programs,” Kristin Yarema, president and CEO of the San Diego-based Poseida, said in a statement.

Roche CEO Thomas Schinecker is pursuing a variety of therapeutic fields to offset falling oncology sales. He has set a high deal pace to restore a development pipeline that was hit by trial setbacks in Alzheimer’s and cancer immunotherapy in 2022.

Roche in December agreed to take over Carmot for US$2.7 billion upfront, seeking to challenge dominant makers of new weight-loss drugs.

The Poseida acquisition will add so-called allogeneic CAR-T cell therapies, which use genetically modified immune cells to attack cancer cells or to treat autoimmune diseases.

Poseida is also working on CAR-T programmes for solid tumours and autoimmune diseases, along with Poseida’s genetic engineering platform and related medicines in early research stages, it added. REUTERS

Share with us your feedback on BT’s products and services

Tags: AcquireBillionCellDealMakerPoseidaRocheTherapeuticsTherapyUS1.5
Yurie Miyazawa

Yurie Miyazawa

Next Post
Thai banks’ bad loans highest in nearly 3 years, but manageable: central bank

Thai banks’ bad loans highest in nearly 3 years, but manageable: central bank

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Forbes 40under40 stands as a distinguished platform revered for its commitment to honoring and applauding the remarkable achievements of exceptional individuals who have yet to reach the age of 40. This esteemed initiative serves as a beacon of inspiration, spotlighting trailblazers across various industries and domains, showcasing their innovation, leadership, and impact on a global scale.

 
 
 
 

NEWS

  • Forbes Magazine
  • Technology
  • Innovation
  • Money
  • Leadership
  • Real Estate
  • Lifestyle
Instagram Facebook Youtube

© 2025 Forbes 40under40. All Rights Reserved.

  • About Us
  • Advertise
  • Contact Us
No Result
View All Result
  • Home
  • Technology
  • Innovation
  • Real Estate
  • Leadership
  • Money
  • Lifestyle

© 2024 Forbes 40under40. All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In